Peer-Reviewed Publication
Prostate2022;82(13):1284-1292.September 1, 2022Journal Article
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
Tao Yang1, Ying Liu1, Shuzhen Chen2, Jiale Tian3, Xuyou Zhu4, Long Zhang4, Wei Wang5, Yingyi Qin6, Jens Richter7, Aseem Anand7, Chengdang Xu1, Yongnan Chi1, Chenyang Wang1, Cuidong Bian1, Denglong Wu1, Zhenfei Li1,8, Shengsong Huang1
1Department of Urology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
2Department of Nuclear Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
3Department of Laboratory Medicine, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
4Department of Pathology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
5Department of Radiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
6Department of Health Statistics, Naval Medical University, Shanghai, China.
7Department of Digital Imaging Biomarkers, EXINI Diagnostics AB, Lund, Sweden.
8State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
Abstract
BACKGROUND: To investigate the prognostic value and potential therapeutic target of the baseline serum hormones in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone.
METHODS: This retrospective study was performed in patients with mCRPC receiving abiraterone acetate (AA) from July 2016 to September 2020. Patients who had serum hormone tests within 2 we…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans